ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0498

A Longitudinal Assessment of Citrulline-specific CD4 T Cells in CCP+ at Risk Subjects and Patients with New-onset Rheumatoid Arthritis

Jing Song1, Scott Presnell1, Cliff Rims2, Matthew Dufort1, Hannah DeBerg1, Peter Linsley2, V. Michael Holers3, Kevin D Deane4, Eddie James1 and Jane Buckner1, 1Benaroya Research Institute at Virginia Mason, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3University of Colorado, Denver, CO, 4University of Colorado Denver Anschutz Medical Campus, Denver, CO

Meeting: ACR Convergence 2022

Keywords: rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: RA – Etiology and Pathogenesis

Session Type: Abstract Session

Session Time: 3:00PM-4:00PM

Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease, in which autoantibodies targeting citrullinated (cit) peptides can be detected prior to diagnosis. We previously reported an increase in cit-specific CD4+ T cells in HLA-DRB1*0401 CCP+ at-risk subjects as compared to CCP– healthy subjects in a cross-sectional cohort. We now extend this study utilizing a longitudinal cohort including HLA-DRB1*0401 CCP– healthy subjects, CCP+ at-risk subjects, RA converters (at-risk individuals sampled just prior to transitioning to RA), and patients with new-onset RA.

Methods: Using DRB1*0401 tetramers containing known citrullinated T cell peptide antigens, we assessed the frequency and surface phenotype of cit-specific CD4+ T cells. To determine the TCR sequences and transcriptome of antigen-specific CD4+ T cells, we also performed Antigen-specific T cell sequencing (Ag-Tseq), which combines robust methods for isolation and enrichment of antigen-specific CD4+ T cells with single-cell RNA-seq (scRNA-seq).

Results: Cit-specific T cells were detected in individuals from all four groups and the frequency of total antigen-specific CD4+ T cells was stable in single individuals over time in each cohort. Notably, CCP+ RA converters had lower frequencies of circulating antigen specific CD4+ T cells than CCP+ at-risk subjects. Additionally, we observed a multiplicity of phenotypes with no single dominant lineage based on antigen specificity, individual subject or disease state. We performed Ag-Tseq on cit-antigen-specific-CD4+ T cells from CCP+ at-risk subjects (n=6), subjects with new onset RA (n=6) and an RA converter (n=1). UMAP analysis identified six distinct clusters (Figure 1). Vimentin- and fibrinogen-specific cells were predominantly found in a cluster dominant for IL7R and ANXA1, CILP-specific cells were found in the naive-like cluster and the activated clusters, whereas enolase-specific cells were present in multiple clusters. Expanded TCR clonotypes from cit-specific CD4+ T cells in CCP+ at-risk, new-onset RA and RA converter subjects were identified at individual time points, some of which were maintained at later time points (Figure 2). To verify the specificity of the expanded TCR clonotypes, we transduced primary human CD4+ T cells with lentivirus expressing the TCR and confirmed activation and expansion of cit-CILP108 TCRs in an at-risk subject. Therefore, cells with this TCR persisted, and were activated and expanded in vivo. This is consistent with our prior study which demonstrated that cit-CILP epitopes were the dominant specificity in CCP+ subjects, which is distinct from new-onset RA.

Conclusion: Cit-specific CD4+ T cells are present and exhibit diverse specificities and cell subset inclusion in both established RA and prior to arthritis development and RA classification. Our findings indicate that some cit-specific CD4+ T cells are activated and expanded in at-risk individuals. This work suggests that the study of these antigen-specific T cell populations may identify novel immune pathways to target therapeutically in RA.

Supporting image 1

Figure 1. A. RA antigen specific cells form 6 clusters using UMAP. B. Antigen-specific cells from Ag-Tseq locate in different clusters.

Supporting image 2

Figure 2. Private shared TCRs persist over time in CCP+ at risk, RA converter and early RA subject.


Disclosures: J. Song, None; S. Presnell, None; C. Rims, None; M. Dufort, None; H. DeBerg, None; P. Linsley, None; V. Holers, Janssen; K. Deane, Werfen; E. James, Janssen, Provention Bio, Bristol-Myers Squibb(BMS), Novartis; J. Buckner, Amgen, Bristol Myers Squibb, Gentiobio, Hot Spot Therapeutics, Janssen, Pfizer, Novo Nordisk, Allen Institute for Immunology, Type 1 Diabetes TrialNet Study Group, La Jolla Institute, Oklahoma Medical Research Foundation, Bristol Myers Squibb Immunology, Colton Center for Autoimmunity at Penn, Board of Scientific Counsellors.

To cite this abstract in AMA style:

Song J, Presnell S, Rims C, Dufort M, DeBerg H, Linsley P, Holers V, Deane K, James E, Buckner J. A Longitudinal Assessment of Citrulline-specific CD4 T Cells in CCP+ at Risk Subjects and Patients with New-onset Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-longitudinal-assessment-of-citrulline-specific-cd4-t-cells-in-ccp-at-risk-subjects-and-patients-with-new-onset-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-longitudinal-assessment-of-citrulline-specific-cd4-t-cells-in-ccp-at-risk-subjects-and-patients-with-new-onset-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology